Internal Medicine

Currently, global interest in glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is surging. Consequently, many Indian clinicians … GLP-1s and Optic Neuropathy: New Data Clarifies RiskRead more

Clinicians often hope that adding newer diabetes therapies can simplify treatment regimens for their patients. Specifically, … Do GLP-1 RAs Truly Help Patients Stop Basal Insulin?Read more

Recent developments have raised serious concerns about dietary supplements safety globally. Consequently, the American College of … Tighter Dietary Supplement Rules: ACP Calls for ActionRead more

Recent clinical evidence has highlighted a potential link between popular diabetes drugs and vision-threatening conditions. Consequently, … Do GLP-1 Agonists Raise Ischemic Optic Neuropathy Risk?Read more

Indeed, GLP-1 receptor agonists are transforming the management of type 2 diabetes and obesity globally. Nevertheless, … Do GLP-1 Receptor Agonists Cause Sudden Vision Loss?Read more

Achieving insulin discontinuation represents a major goal for many individuals managing type 2 diabetes (T2D). Furthermore, … Do GLP-1s Really Help Type 2 Diabetes Patients Stop Insulin?Read more

Many health practitioners daily recommend nutritional products to their patients. Consequently, understanding the state of dietary … Is Your Patient’s Supplement Safe? ACP Demands ReformRead more

Consequently, the growing use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) has revolutionized type 2 diabetes management. … Are GLP-1 Receptor Agonists Harming Patient Vision?Read more

Evaluating clinically suspected acute pulmonary embolism in oncological cohorts presents a major medical challenge. Historically, standard … YEARS Algorithm Safely Spares CTPA in Cancer PatientsRead more

Amyloid-targeting therapies represent a significant leap forward in the fight against neurodegeneration. However, the long-term clinical … How Amyloid Clearance Halts Alzheimer’s Brain DecayRead more